ClinicalTrials.gg
CompletedNCT02864381Updated Sep 18, 2020Results posted

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of Andecaliximab and Nivolumab in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Gilead Sciences. Completed at 34 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-18.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.

02

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed inoperable locally advanced or adenocarcinoma of the stomach or GEJ which have progressed on at least 1 prior systemic therapy or for unresectable/metastatic disease
  • (ECOG) performance score of ≤ 1
  • according to Response Criteria in Solid Tumors () v1.1
  • Tumor sites that can be accessed for repeat
  • Archival tumor tissue, preferably obtained from the most recent available biopsy; there must be adequate tissue for a Cochran-Mantel Haenszel (CMH) test stratified by programmed death ligand 1 () stratification test, as assessed by central pathologist
  • Individuals not receiving anticoagulant medication must have an (INR) ≤ 1.5 and activated partial thromboplastin (aPTT) ≤ 1.5 x (ULN)
  • Required baseline laboratory data as outlined in protocol

Key Exclusion Criteria:

  • Individuals who have received only or adjuvant therapy for gastric adenocarcinoma
  • Radiotherapy within 28 days of randomization
  • Uncontrolled intercurrent illness as outlined in protocol
  • History of a concurrent or second except for those outlined in protocol
  • Major surgery, within 28 days of first dose of study drug
  • Known positive status for (HIV)
  • Known acute or chronic-active infection with virus (HBV) or virus (HCV)
  • Chronic daily treatment with oral (dose of > 10 mg/day prednisone equivalent) or other medications within 14 days of randomization
  • Known or suspected central nervous system metastases
  • Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of randomization
  • Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibiotics
  • Current or history of pneumonitis or interstitial lung disease
  • Active known or suspected disease with exceptions noted in protocol.
  • History of bone marrow, stem cell, or allogenic organ transplantation

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Andecaliximab + Nivolumab

    Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).

    Drug: Andecaliximab · Drug: Nivolumab

  • Active comparator
    Nivolumab

    Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).

    Drug: Nivolumab

Interventions

  • 800 mg administered via IV infusion

    Also known as: GS-5745

  • 3 mg/kg administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with confirmed overall best response of complete response (CR) or partial response (PR) after starting study drug but before starting any new chemotherapy or radiotherapy as assessed by the investigator according to Response Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 41 weeks

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the interval in months from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. The first definitive progressive disease (PD) was defined as the first radiation therapy, the first clinical PD, and the first confirmed imaging PD, whichever came first. Participants without PD or death and participants with PD after starting new anti-cancer therapy are censored at the last tumor assessment date.

    Time frame: Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months

  2. Overall Survival (OS)

    OS was defined as the interval from the date of randomization to death from any cause. Surviving participants are censored at the last date known alive.

    Time frame: Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.0 months

  3. Duration of Response (DOR)

    DOR was defined as the interval from the date of the first response (complete or partial response) was achieved to the earlier of the first documentation of definitive disease progression or death from any cause.

    Time frame: Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months

  4. Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participants administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events that are defined as AEs with onset dates on or after the first dose of andecaliximab/nivolumab and up to 30 days after permanent discontinuation of andecaliximab or 5 months after permanent discontinuation of nivolumab, or led to premature discontinuation of andecaliximab or nivolumab.

    Time frame: Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months

  5. Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities

    Treatment-emergent (Chemistry, Hematology, Coagulation, and Urinalysis) laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of andecaliximab plus 30 days or nivolumab plus 5 months. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment-emergent. Percentage of participants with any postbaseline Grade 1 or higher laboratory abnormality is reported.

    Time frame: Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months

07

Results

Posted Sep 18, 2020

Participant flow

Participants were enrolled at study sites in Australia, Europe, and the United States. The first participant was screened on 01 September 2016. The last study visit occurred on 23 August 2019.

Participant flow — Overall Study
MilestoneAndecaliximab + NivolumabNivolumab
Started7272
Completed00
Not completed7272
Withdrew: Death5861
Withdrew: Withdrew consent56
Withdrew: Reason unknown73
Withdrew: Lost to follow-up11
Withdrew: Investigator's discretion10
Withdrew: Protocol violation01

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with confirmed overall best response of complete response (CR) or partial response (PR) after starting study drug but before starting any new chemotherapy or radiotherapy as assessed by the investigator according to Response Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 41 weeks
Reported as:
Mean · percentage of participants
Objective Response Rate (ORR)
percentage of participantsAndecaliximab + NivolumabNivolumab
Objective Response Rate (ORR)9.7 (4.0 to 19.0)6.9 (2.3 to 15.5)
Statistical analysis
  • Andecaliximab + Nivolumab vs Nivolumab · Cochran-Mantel-Haenszel · p = 0.8 (P-value is derived from Cochran-Mantel Haenszel (CMH) test stratified by programmed death ligand 1 (PD-L1) stratification factor status.) · Odds ratio (or): 1.5 · 95% CI 0.4 to 6.1Odds Ratio is derived from CMH test stratified by PD-L1 stratification factor status, the Nivolumab alone arm serves as the reference.
SecondaryProgression Free Survival (PFS)

PFS was defined as the interval in months from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. The first definitive progressive disease (PD) was defined as the first radiation therapy, the first clinical PD, and the first confirmed imaging PD, whichever came first. Participants without PD or death and participants with PD after starting new anti-cancer therapy are censored at the last tumor assessment date.

Time frame:
Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsAndecaliximab + NivolumabNivolumab
Progression Free Survival (PFS)1.840 (1.807 to 2.004)1.856 (1.741 to 1.906)
Statistical analysis
  • Andecaliximab + Nivolumab vs Nivolumab · Log Rank · p = 0.306 (P-value is derived from log-rank test stratified by PD-L1 stratification factor status.) · Hazard ratio (hr): 0.836 · 95% CI 0.589 to 1.189Hazard ratio is derived from Cox model stratified by PD-L1 stratification factor status, the Nivolumab alone arm serves as the reference.
SecondaryOverall Survival (OS)

OS was defined as the interval from the date of randomization to death from any cause. Surviving participants are censored at the last date known alive.

Time frame:
Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.0 months
Reported as:
Median · months
Overall Survival (OS)
monthsAndecaliximab + NivolumabNivolumab
Overall Survival (OS)7.162 (4.797 to NA)5.881 (3.483 to 10.908)
Statistical analysis
  • Andecaliximab + Nivolumab vs Nivolumab · Log Rank · p = 0.312 (P-value is derived from log-rank test stratified by PD-L1 stratification factor status.) · Hazard ratio (hr): 0.786 · 95% CI 0.491 to 1.257Hazard ratio is derived from Cox model stratified by PD-L1 stratification factor status, the Nivolumab alone arm serves as the reference.
SecondaryDuration of Response (DOR)

DOR was defined as the interval from the date of the first response (complete or partial response) was achieved to the earlier of the first documentation of definitive disease progression or death from any cause.

Time frame:
Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months
Reported as:
Median · months
Duration of Response (DOR)
monthsAndecaliximab + NivolumabNivolumab
Duration of Response (DOR)NA (1.807 to NA)NA (2.037 to NA)
SecondaryPercentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participants administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events that are defined as AEs with onset dates on or after the first dose of andecaliximab/nivolumab and up to 30 days after permanent discontinuation of andecaliximab or 5 months after permanent discontinuation of nivolumab, or led to premature discontinuation of andecaliximab or nivolumab.

Time frame:
Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
percentage of participantsAndecaliximab + NivolumabNivolumab
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)98.697.1
SecondaryPercentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities

Treatment-emergent (Chemistry, Hematology, Coagulation, and Urinalysis) laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of andecaliximab plus 30 days or nivolumab plus 5 months. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment-emergent. Percentage of participants with any postbaseline Grade 1 or higher laboratory abnormality is reported.

Time frame:
Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
percentage of participantsAndecaliximab + NivolumabNivolumab
Alanine aminotransferase increased20.027.1
Alkaline phosphatase increased45.140.0
Aspartate aminotransferase increased30.028.6
Blood bilirubin increased8.511.4
Chronic Kidney Disease16.925.7
Creatinine increased1.47.1
Hyperglycemia22.518.6
Hyperkalemia7.15.7
Hypermagnesemia2.81.4
Hypoalbuminemia35.238.6
Hypoglycemia11.34.3
Hypokalemia10.011.4
Hypomagnesemia5.64.3
Hyponatremia28.240.0
Hypophosphatemia11.38.6
Lipase increased11.38.6
Serum amylase increased9.97.1
Activated partial thromboplastin time prolonged2.619.4
International Normalized Ratio (INR) increased2.612.5
Anemia53.556.5
Lymphocytes, Typical count decreased35.227.5
Lymphocytes, Typical count increased4.20
Neutrophil count decreased5.65.8
Platelet count decreased8.55.8
White blood cell decreased9.97.2
Proteinuria (Dipstick)29.431.3

Adverse events

Collected over All-Cause Mortality: Andecaliximab + Nivolumab median follow-up time: 28.2 months; Nivolumab median follow-up time: 28.4 months; Adverse Events: Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andecaliximab + Nivolumab61/72 (84.7%)42/71 (59.2%)66/71 (93%)
Nivolumab62/72 (86.1%)38/70 (54.3%)62/70 (88.6%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventAndecaliximab + NivolumabNivolumab
Abdominal painGastrointestinal disorders3/716/70
AnaemiaBlood and lymphatic system disorders5/714/70
DysphagiaGastrointestinal disorders4/714/70
Intestinal obstructionGastrointestinal disorders4/710/70
Gastrointestinal haemorrhageGastrointestinal disorders0/713/70
Septic shockInfections and infestations1/713/70
AscitesGastrointestinal disorders3/712/70
HaematemesisGastrointestinal disorders3/710/70
NauseaGastrointestinal disorders3/712/70
Small intestinal obstructionGastrointestinal disorders3/710/70
Most frequent other events
Showing 10 of 44
Most frequent other events
EventAndecaliximab + NivolumabNivolumab
NauseaGastrointestinal disorders27/7117/70
FatigueGeneral disorders22/7125/70
Decreased appetiteMetabolism and nutrition disorders24/7120/70
VomitingGastrointestinal disorders22/7118/70
AstheniaGeneral disorders21/7112/70
ConstipationGastrointestinal disorders18/7118/70
Abdominal painGastrointestinal disorders11/7116/70
AnaemiaBlood and lymphatic system disorders14/7114/70
DiarrhoeaGastrointestinal disorders14/719/70
DysphagiaGastrointestinal disorders12/718/70

Baseline characteristics

The Intent-to-treat Analysis Set included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)Andecaliximab + NivolumabNivolumabTotal
Mean58 ± 12.159 ± 11.859 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Andecaliximab + NivolumabNivolumabTotal
Female232245
Male495099
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab + NivolumabNivolumabTotal
Race — Asian112
Race — Black202
Race — White5561116
Race — Not Permitted12820
Race — Other224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab + NivolumabNivolumabTotal
Ethnicity — Hispanic or Latino235
Ethnicity — Not Hispanic or Latino5961120
Ethnicity — Not Permitted11819
Region of Enrollment
Region of Enrollment(participants)Andecaliximab + NivolumabNivolumabTotal
United Kingdom171835
United States141428
Belgium51015
France9615
Poland5914
Spain10414
Italy8513
Australia257
Hungary213
08

Study locations

34 sites
  • Los Angeles, California 90095, United States
  • San Francisco, California 94158, United States
  • Chicago, Illinois 60637, United States
  • Fort Wayne, Indiana 46845, United States
  • Saint Louis, Missouri 63110, United States
  • New York, New York 10065, United States
  • Albury, New South Wales 2640, Australia
  • Wahroonga, New South Wales 2076, Australia
  • Douglas, Queensland 4818, Australia
  • Hobart, Tasmania 7000, Australia
  • La Louvière, Hainaut 7100, Belgium
  • Gent, Oost-Vlaanderen 9000, Belgium
  • Leuven, Vlaams Brabant 3000, Belgium
  • Brest, Finistère 29609, France
  • Reims, Marne 51092, France
  • Villejuif, Val-de-Marne 94805, France
  • Budapest, H-1097, Hungary
  • Debrecen, 4032, Hungary
  • Meldola, Forli-Cesena 47014, Italy
  • Genova, Ligura 16128, Italy
  • Milano, Lombardia 20132, Italy
  • Pisa, Toscana 56126, Italy
  • Brzozow, Podkarpackie 36-200, Poland
  • Poznań, 60-693, Poland
  • Warszawa, 02-781, Poland
  • Majadahonda, Madrid 28222, Spain
  • Barcelona, 08003, Spain
  • Barcelona, 08035, Spain
  • Bristol, BS2 8ED, United Kingdom
  • Edgbaston, B15 2PR, United Kingdom
  • London, EC1A 7BE, United Kingdom
  • London, WC1E 6BT, United Kingdom
  • Manchester, M20 4BX, United Kingdom
  • Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya M, Inzunza D, Liu J, Patterson SD, Zhou J, He J, Thai D, Bhargava P, Brachmann CB, Cantenacci DVT. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. J Immunother Cancer. 2021 Dec;9(12):e003580. doi: 10.1136/jitc-2021-003580. PubMed 34893523 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Nov 2017, 14 months.

Results were first posted in Sep 2020, 2 years 10 months after primary completion. A results delay was requested in Nov 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2016
First posted
Aug 12, 2016
StartActual
Sep 1, 2016
Primary completionActual
Nov 8, 2017
CompletionActual
Aug 23, 2019
Results delay requested
Nov 1, 2018
Results first posted
Sep 18, 2020
Last update
Sep 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02864381
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 12, 2016
Start date
Sep 1, 2016
Primary completion
Nov 8, 2017
Completion
Aug 23, 2019
Results posted
Sep 18, 2020
Last update
Sep 18, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion